ACR Journals On Air

American College of Rheumatology
undefined
Nov 10, 2026 • 20min

Medication-induced rheumatic syndromes

Ambreesh Chawla, a Cleveland Clinic rheumatologist and medical educator, previews a session on medication-induced rheumatic syndromes. He explores dupilumab-associated enthesitis, PPI-related cutaneous lupus, and DPP-4 inhibitor–linked inflammatory arthritis. Chawla also discusses diagnostic dilemmas, his path from biomedical engineering to rheumatology, innovative teaching methods, and making the most of ACR Convergence.
undefined
Oct 27, 2026 • 27min

Assessing Reliability of an Electronic Gout Flare Assessment Protocol

Misti Paudel, a rheumatology researcher trained in clinical epidemiology, and Shravani Chitineni, a biostatistician and statistical programmer, discuss electronic gout flare monitoring in the TRUST trial. They compare electronic and telephone assessments, explore ways to reduce patient burden, and examine the challenges of embedding innovation in ongoing research. They also share their interdisciplinary career paths and the value of patient-centered study design.
undefined
Oct 13, 2026 • 26min

Autoimmune Disease Risk with GLP-1RA, DPP-4i and SGLT2i Treatment in Patients with Diabetes

Arjun Mahajan, a physician-scientist studying autoimmune disease through data science, and Jeffrey Sparks, a Harvard rheumatologist researching rheumatic disease epidemiology, examine newer diabetes medications and autoimmune disease risk. They unpack federated health data, target-trial methods, disease-specific associations, biological mechanisms, study limitations, unexpected findings, and the mentorship that shaped their work.
undefined
Sep 29, 2026 • 21min

The Gut-Heart Axis in Systemic Sclerosis

What does the gut have to do with the heart in scleroderma? Quite a lot, as it turns out. In this episode, we talk with Dr. Zsuzsanna McMahan about new findings from the GENISOS cohort exploring the relationship between gastrointestinal and cardiac manifestations in systemic sclerosis, including the striking timing and strength of these associations and what they might reveal about shared disease mechanisms. Then we shift gears to the realities of academic medicine: Dr. McMahan shares lessons from moving from Johns Hopkins back to UT Houston, rebuilding clinical and research programs, forging new collaborations, and, perhaps most importantly, deciding what to say yes to and what to leave on the table The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort
undefined
Sep 15, 2026 • 33min

Measuring the Impact: MRI Response of SI Joints in Youth with Axial SpA

Pamela Weiss, a pediatric rheumatologist, epidemiologist, and physician-scientist at Children’s Hospital of Philadelphia, discusses axial juvenile spondyloarthritis. She explores MRI changes in sacroiliac joints after TNF inhibitor treatment, how imaging compares with patient-reported outcomes, and why lingering inflammation matters. She also shares her path into research and the mentors who shaped her career.
undefined
Sep 1, 2026 • 31min

Risk Factors for Relapse in ANCA Vasculitis

In this episode, we speak with Dr. Ellen Romich about her post hoc analysis of the RITAZAREM trial, exploring factors associated with relapse in ANCA-associated vasculitis. She discusses the study design, key findings—including the roles of rituximab, azathioprine, CD19 positivity, ANCA status, and immune reconstitution—and the clinical implications and limitations of the work. Dr. Romich also shares her path into rheumatology, how she became involved in the analysis, and what questions she hopes to tackle next. Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab
undefined
5 snips
Aug 18, 2026 • 30min

Significance of a Positive ANA in Patients Without Autoimmune Diseases

Vivian Kawai, a University of Alabama rheumatologist and data-driven researcher, joins medical student and clinical informatics researcher Matthew Chung. They explore what high-titer ANA results may signal without autoimmune disease, how electronic health records and PheWAS uncovered striking liver-disease associations, and the study’s limitations. They also discuss mentorship, finding research opportunities, and Matthew’s path toward medicine.
undefined
Aug 4, 2026 • 42min

RA Inference in EHR

In this episode, we explore how artificial intelligence and machine learning are advancing the use of electronic health record data in rheumatology. Dr. Kat discusses the development and validation of a natural language processing–based model to infer rheumatoid arthritis disease activity from structured and unstructured clinical data, its application in studying cardiovascular outcomes, and the challenges of deploying predictive models across different health systems. The conversation also examines the future of real-world evidence generation, the practical limitations of AI in clinical research, and Dr. Kat's career journey, offering insights and advice for the next generation of physician-scientists.
undefined
Jul 21, 2026 • 33min

Distilling Still Disease: Interstitial Lung Disease and Still

In this episode, Michael J. Ombrello, MD, explores how our understanding of Still's disease has evolved, from recognizing interstitial lung disease as a key manifestation to uncovering the immunologic and genetic factors that may shape disease severity. He discusses insights from a National Institutes of Health natural history study, including interferon signatures, HLA associations, drug-associated immunologic reactions, and exome sequencing, and explains what these findings could mean for future diagnosis, risk stratification, and treatment. The conversation also turns to Dr. Ombrello's own career path, the personal experiences that inspire his research, and the mentors who helped shape his journey as a physician-scientist. Type I Interferon Signature is Associated With Lung Disease, Drug-Associated Immune Reactions, and Genetic Variation in Interferon-Linked Pathways in Still Disease
undefined
Jul 7, 2026 • 37min

GLP-1 receptor agonists in the RISE registry

In this episode, Nicholas P. McCormic discusses new real-world research from the RISE registry examining the use of GLP-1 receptor agonists in patients with rheumatic and musculoskeletal diseases. He explains the motivation behind the study, its design, and key findings on medication use, weight loss, and differences between semaglutide and tirzepatide, while highlighting important considerations for clinicians and patients. Nick also shares insights into the strengths and limitations of using registry data before reflecting on his journey from psychology and sociology to earning a Ph.D. focused on chronic disease management and rheumatology, offering advice for aspiring researchers and a look at his future work.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app